Evaluating the effect of Ivermectin on covid 19 patients

Phase 2

Conditions: COVID 19.
Corona virus infection, unspecified
U07.1

Registration Number: IRCT20200404046937N4

Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 60

Inclusion Criteria

Age =18 years
Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19
Hospitalized
Satisfaction to participate in the study
Acceptance of non-participation in another study before the 28th day of the study

Exclusion Criteria

Patients with a history of allergic reaction to Ivermectin
Renal dysfunction
Liver dysfunction
Pregnancy or deciding to get pregnant or breastfeeding

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Viral diagnostic test. Timepoint: The first day of the study. Method of measurement: Polymerase chain reaction.;Duration of hospitalization. Timepoint: Time of dyscharge. Method of measurement: Patient file.

Secondary Outcome Measures

Name	Time	Method
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Daily. Method of measurement: Patient file.;Dyspnea. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cough. Timepoint: Daily. Method of measurement: Patients interview and patient file.;Cell blood count. Timepoint: The first day of the study and the end of the study. Method of measurement: Lab test.;C_reactive protein. Timepoint: The first day of the study and the end of the study. Method of measurement: Lab test.;CT scan. Timepoint: The first day of the study and the end of the study. Method of measurement: CT scan set.